Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM30WDL)

• Drug Name: SYM2081 Drug Info
• Synonyms: KRKRAOXTGDJWNI-DMTCNVIQSA-L; (2S,4R)-2-amino-4-methylpentanedioate; [3H](2S,4R)-4-methylglutamate; [3H]SYM2081; [(3)H]4MG; (2S,4R)-Me-Glu; GTPL4317; GTPL4075; compound 52 [PMID:

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 21117106
  TTD Drug ID: DM30WDL

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor ionotropic kainate 2 (GRIK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[5]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[5]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[5]
2,4-epi-neodysiherbaine	DMZRY0Q	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Glutamate receptor ionotropic kainate 3 (GluK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[6]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[6]
UBP310	DMVQL3J	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Glutamate receptor ionotropic kainate 1 (GRIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[10]
LY293558	DM4N6EK	Pain	MG30-MG3Z	Phase 2	[11]
NS 1209	DM9EFH0	Epilepsy	8A60-8A68	Phase 2	[12]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[13]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[13]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[4]
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[14]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[15]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[4]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Excitatory amino acid transporter 1 (SLC1A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D-aspartic acid	DM7Z892	Discovery agent	N.A.	Investigative	[2]
[3H]ETB-TBOA	DMWGY61	Discovery agent	N.A.	Investigative	[16]
DL-TBOA	DM2HGNU	Discovery agent	N.A.	Investigative	[17]
UCPH-101	DMTQEDA	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Glutamate receptor ionotropic kainate 4 (GluK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[7]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[7]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Glutamate receptor ionotropic kainate 5 (GRIK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[8]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[8]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Excitatory amino acid transporter 2 (SLC1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D-aspartic acid	DM7Z892	Discovery agent	N.A.	Investigative	[19]
[3H]ETB-TBOA	DMWGY61	Discovery agent	N.A.	Investigative	[16]
DL-TBOA	DM2HGNU	Discovery agent	N.A.	Investigative	[17]
threo-3-methylglutamate	DMOE3IJ	Discovery agent	N.A.	Investigative	[3]
WAY-213613	DMMXL4E	Discovery agent	N.A.	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Excitatory amino acid transporter 1 (SLC1A3)	TT8WRDA	EAA1_HUMAN	Modulator	[2]
Excitatory amino acid transporter 2 (SLC1A2)	TT2F078	EAA2_HUMAN	Inhibitor	[3]
Glutamate receptor ionotropic kainate 1 (GRIK1)	TT0MYE2	GRIK1_HUMAN	Agonist	[4]
Glutamate receptor ionotropic kainate 2 (GRIK2)	TT0K5RG	GRIK2_HUMAN	Agonist	[5]
Glutamate receptor ionotropic kainate 3 (GluK3)	TTNP6O2	GRIK3_HUMAN	Agonist	[6]
Glutamate receptor ionotropic kainate 4 (GluK4)	TTQV6BO	GRIK4_HUMAN	Agonist	[7]
Glutamate receptor ionotropic kainate 5 (GRIK5)	TTO6LI7	GRIK5_HUMAN	Agonist	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4075).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868).
• [3] Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
• [9] Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45.
• [10] Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
• [11] Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
• [12] The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
• [13] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [14] Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
• [15] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [16] Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302.
• [17] DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
• [18] Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. J Med Chem. 2009 Feb 26;52(4):912-5.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 869).
• [20] Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinit... Mol Pharmacol. 2005 Oct;68(4):974-82.